image

HWGB Biotech aims to provide a comprehensive range of big health products and solutions that adopts a preventive measure readily available to give a peace of mind of many around the world.

Backed by a panel of experienced consultants with relevant experience in the healthcare and technology industry in regards to matters involving healthcare and biotechnology.

+603-2143 8811 OR enquiry@hwgbbiotech.com

Media Details

  • Home
  • Media
  • Details
  2020-11-18 21:32:40

Commencement Of Pivotal Phase IV Clinical Study: The Team Behind The Scene

- The Company Has Lined Up A Strong Team To Support The Study

KUALA LUMPUR, 18 NOVEMBER 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code:9601) has begun its Phase IV clinical study on COVID-19 vaccine with E-MO Biology Inc (“EBI”) whose key business revolves around biology research and development activities besides indicating booster polio vaccine can reduce COVID-19 SARS-COV-2 infection and severity.
 
The Phase IV clinical study will be led by EBI founder and managing director, Dr. Xie Qiyi (“Dr. Xie”).
Back
image

HWGB BIOTECH SDN BHD (Formerly known as HWG Consortium Sdn Bhd) [Company Number: 201201022032 (1006524-T)]

Our Business

Quick Links

Information

Privacy Policy   |  PDPA   |  Terms of Use

2020 HWGB Biotech. All rights Reserved.